These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

537 related items for PubMed ID: 30391211

  • 61. Assessment of the clinical application of detecting EGFR, KRAS, PIK3CA and BRAF mutations in patients with non-small cell lung cancer using next-generation sequencing.
    Xu X, Yang Y, Li H, Chen Z, Jiang G, Fei K.
    Scand J Clin Lab Invest; 2016 Sep; 76(5):386-92. PubMed ID: 27215271
    [Abstract] [Full Text] [Related]

  • 62. Clinical Impact of Hybrid Capture-Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer.
    Rozenblum AB, Ilouze M, Dudnik E, Dvir A, Soussan-Gutman L, Geva S, Peled N.
    J Thorac Oncol; 2017 Feb; 12(2):258-268. PubMed ID: 27865871
    [Abstract] [Full Text] [Related]

  • 63. Clinical next-generation sequencing in patients with non-small cell lung cancer.
    Hagemann IS, Devarakonda S, Lockwood CM, Spencer DH, Guebert K, Bredemeyer AJ, Al-Kateb H, Nguyen TT, Duncavage EJ, Cottrell CE, Kulkarni S, Nagarajan R, Seibert K, Baggstrom M, Waqar SN, Pfeifer JD, Morgensztern D, Govindan R.
    Cancer; 2015 Feb 15; 121(4):631-9. PubMed ID: 25345567
    [Abstract] [Full Text] [Related]

  • 64. Survival outcomes and prognostic factors of lung cancer patients with the MET exon 14 skipping mutation: A single-center real-world study.
    Gow CH, Hsieh MS, Chen YL, Liu YN, Wu SG, Shih JY.
    Front Oncol; 2023 Feb 15; 13():1113696. PubMed ID: 36969059
    [Abstract] [Full Text] [Related]

  • 65. Case report: HER2 amplification as a resistance mechanism to crizotinib in NSCLC with MET exon 14 skipping.
    Ding G, Wang J, Ding P, Wen Y, Yang L.
    Cancer Biol Ther; 2019 Feb 15; 20(6):837-842. PubMed ID: 30744539
    [Abstract] [Full Text] [Related]

  • 66. Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative.
    Lim SM, Kim EY, Kim HR, Ali SM, Greenbowe JR, Shim HS, Chang H, Lim S, Paik S, Cho BC.
    Oncotarget; 2016 Apr 26; 7(17):24172-8. PubMed ID: 26992220
    [Abstract] [Full Text] [Related]

  • 67. Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project.
    Bubendorf L, Dafni U, Schöbel M, Finn SP, Tischler V, Sejda A, Marchetti A, Thunnissen E, Verbeken EK, Warth A, Sansano I, Cheney R, Speel EJM, Nonaka D, Monkhorst K, Hager H, Martorell M, Savic S, Kerr KM, Tan Q, Tsourti Z, Geiger TR, Kammler R, Schulze K, Das-Gupta A, Shames D, Peters S, Stahel RA, Lungscape Consortium.
    Lung Cancer; 2017 Sep 26; 111():143-149. PubMed ID: 28838386
    [Abstract] [Full Text] [Related]

  • 68. Prospective Clinical Integration of an Amplicon-Based Next-Generation Sequencing Method to Select Advanced Non-Small-Cell Lung Cancer Patients for Genotype-Tailored Treatments.
    Zugazagoitia J, Rueda D, Carrizo N, Enguita AB, Gómez-Sánchez D, Díaz-Serrano A, Jiménez E, Mérida A, Calero R, Lujan R, De Miguel E, Gámez P, Díaz-Hellín V, Nuñez JA, Iglesias L, Ferrer I, Paz-Ares L, Ponce-Aix S.
    Clin Lung Cancer; 2018 Jan 26; 19(1):65-73.e7. PubMed ID: 28780976
    [Abstract] [Full Text] [Related]

  • 69. Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations.
    Liu X, Jia Y, Stoopler MB, Shen Y, Cheng H, Chen J, Mansukhani M, Koul S, Halmos B, Borczuk AC.
    J Clin Oncol; 2016 Mar 10; 34(8):794-802. PubMed ID: 26215952
    [Abstract] [Full Text] [Related]

  • 70. Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation.
    Fujino T, Suda K, Koga T, Hamada A, Ohara S, Chiba M, Shimoji M, Takemoto T, Soh J, Mitsudomi T.
    J Hematol Oncol; 2022 Jun 11; 15(1):79. PubMed ID: 35690785
    [Abstract] [Full Text] [Related]

  • 71. Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency.
    Bustamante Alvarez JG, Janse S, Owen DH, Kiourtsis S, Bertino EM, He K, Carbone DP, Otterson GA.
    Clin Lung Cancer; 2021 Jul 11; 22(4):e519-e527. PubMed ID: 33414052
    [Abstract] [Full Text] [Related]

  • 72. c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas.
    Mignard X, Ruppert AM, Antoine M, Vasseur J, Girard N, Mazières J, Moro-Sibilot D, Fallet V, Rabbe N, Thivolet-Bejui F, Rouquette I, Lantuejoul S, Cortot A, Saffroy R, Cadranel J, Lemoine A, Wislez M.
    J Thorac Oncol; 2018 Dec 11; 13(12):1962-1967. PubMed ID: 30149144
    [Abstract] [Full Text] [Related]

  • 73. Distinct MET Protein Localization Associated With MET Exon 14 Mutation Types in Patients With Non-small-cell Lung Cancer.
    Qiu T, Li W, Zhang T, Xing P, Huang W, Wang B, Chu L, Guo L, Liu X, Li Y, Ying J, Li J.
    Clin Lung Cancer; 2018 Jul 11; 19(4):e391-e398. PubMed ID: 29338938
    [Abstract] [Full Text] [Related]

  • 74. Mutation landscape and tumor mutation burden analysis of Chinese patients with pulmonary sarcomatoid carcinomas.
    Liang X, Li Q, Xu B, Hu S, Wang Q, Li Y, Zong Y, Zhang S, Li C.
    Int J Clin Oncol; 2019 Sep 11; 24(9):1061-1068. PubMed ID: 31065835
    [Abstract] [Full Text] [Related]

  • 75. New Verse for a Familiar Song: Small Molecule Inhibitors for MET exon 14 Skipping Non-Small Cell Lung Cancer.
    Le X, Heymach JV.
    Oncologist; 2020 Oct 11; 25(10):822-825. PubMed ID: 33400286
    [Abstract] [Full Text] [Related]

  • 76. Sensitive and specific detection of EML4-ALK rearrangements in non-small cell lung cancer (NSCLC) specimens by multiplex amplicon RNA massive parallel sequencing.
    Moskalev EA, Frohnauer J, Merkelbach-Bruse S, Schildhaus HU, Dimmler A, Schubert T, Boltze C, König H, Fuchs F, Sirbu H, Rieker RJ, Agaimy A, Hartmann A, Haller F.
    Lung Cancer; 2014 Jun 11; 84(3):215-21. PubMed ID: 24674157
    [Abstract] [Full Text] [Related]

  • 77. Refining patient selection of MET-activated non-small cell lung cancer through biomarker precision.
    Lai GGY, Guo R, Drilon A, Shao Weng Tan D.
    Cancer Treat Rev; 2022 Nov 11; 110():102444. PubMed ID: 36108503
    [Abstract] [Full Text] [Related]

  • 78. Targeted Tissue and Cell-Free Tumor DNA Sequencing of Advanced Lung Squamous-Cell Carcinoma Reveals Clinically Significant Prevalence of Actionable Alterations.
    Lam VK, Tran HT, Banks KC, Lanman RB, Rinsurongkawong W, Peled N, Lewis J, Lee JJ, Roth J, Roarty EB, Swisher S, Talasaz A, Futreal PA, Papadimitrakopoulou V, Heymach JV, Zhang J.
    Clin Lung Cancer; 2019 Jan 11; 20(1):30-36.e3. PubMed ID: 30279110
    [Abstract] [Full Text] [Related]

  • 79. Optimizing Mutation and Fusion Detection in NSCLC by Sequential DNA and RNA Sequencing.
    Cohen D, Hondelink LM, Solleveld-Westerink N, Uljee SM, Ruano D, Cleton-Jansen AM, von der Thüsen JH, Ramai SRS, Postmus PE, Graadt van Roggen JF, Hoppe BPC, Clahsen PC, Maas KW, Ahsmann EJM, Ten Heuvel A, Smedts F, van Rossem RN, van Wezel T.
    J Thorac Oncol; 2020 Jun 11; 15(6):1000-1014. PubMed ID: 32014610
    [Abstract] [Full Text] [Related]

  • 80. [MET Exon 14 Skipping Mutations in Non-small Cell Lung Cancer].
    Yin L, Lu Y.
    Zhongguo Fei Ai Za Zhi; 2018 Jul 20; 21(7):553-559. PubMed ID: 30037377
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 27.